Top Healthcare Investors in 2026 (109 Firms Reviewed)

The top healthcare investors of 2026 are concentrating capital around four themes: AI-native clinical and administrative workflow, AI-accelerated drug discovery and TechBio, value-based and risk-bearing care delivery, and precision diagnostics and research tools. This is the definitive list of the healthcare investment firms actually deploying against them — 109 firms across venture, growth, corporate and family office capital.

Every firm below was checked against its own published materials, and the list is crowdsourced from the Crowdcreate expert network of healthcare founders, operators and investors. We have grouped these firms into four categories and listed them unranked — and we explain below exactly why we did not rank them by deal count.

The 2026 Healthcare Funding Market, in Numbers

The market that produced this list is narrower and more concentrated than the one that existed three years ago. According to Rock Health, US digital health startups raised $14.2 billion in 2025 across 482 deals — a 35% increase in dollars over 2024’s $10.5 billion, and the highest annual total since 2022.

Deal count fell 5% over the same period, from 509 to 482, which pushed average deal size up from $20.7 million to $29.3 million. Raises above $100 million accounted for 42% of all funding, the highest share since 2021, and Rock Health noted that removing the top nine companies by dollars raised would drop the 2025 total below 2024’s. Capital is pooling around fewer companies.

The exit window also reopened: M&A volume rose 61% year over year, alongside five digital health IPOs. That momentum carried into 2026, with $4 billion raised across 110 deals in the first quarter.

What Is a Healthcare Investor?

Healthcare investors are firms that provide capital to companies across biotechnology, medical devices, diagnostics, healthcare services and digital health. They range from firms that invent and incorporate companies themselves, to crossover funds that follow a drug from a Series A through to the public markets, to corporate venture arms whose strategic value is distribution inside a payer or health system, to family offices deploying private wealth with no fund life to worry about.

The label “healthcare investor” covers all of them, and the difference between them matters enormously to a founder deciding who to pitch. That is why this list is organised by type of capital rather than by a single ranking.

How We Selected These Healthcare Investors

• Verified healthcare activity. Every firm on this list has healthcare, life sciences, biotech, medtech or digital health investments disclosed on its own website or in its own filings. We did not add a firm on the strength of a third-party database entry alone.
• Published strategy and portfolio. We reviewed each firm’s own description of its strategy, portfolio and recent activity as published on its website and in its announcements, rather than relying on secondary summaries.
• Documented recent deployment. We required evidence of continuing healthcare investment activity, drawn from the firm’s own announcements, its portfolio companies’ announcements, or SEC filings.
• Crowdsourced input from our expert network. We asked healthcare founders, operators and investors in the Crowdcreate network which firms they would actually take a meeting with.

What we did not do. We did not rank these firms by returns, IRR or assets under management, and we did not license deal-count data from a commercial database. Per-investor deal counts are not published by the firms themselves — they exist only inside paid platforms — so a ranked “deal volume” leaderboard cannot be built from primary sources. Rather than estimate, we have grouped these firms into four categories and listed them unranked. Where a firm does not publish its portfolio, we say so rather than guess.

Healthcare VC and Growth Investors

These are the firms that define venture and growth-stage healthcare capital in the US — a mix of company creators, crossover funds and multi-strategy platforms. Several of them can fund the same company from incorporation through to the public markets.

OrbiMed ↗

Best For: Founders who expect to raise repeatedly, from seed to public markets

OrbiMed is a healthcare investment firm headquartered in New York that, by its own account, manages over $17 billion in assets across private equity funds, public equity funds and royalty/credit funds. Its team of more than 145 professionals works out of New York, London, San Francisco, Shanghai, Hong Kong, Mumbai and Herzliya. The firm invests from seed-stage venture through to large publicly traded companies, and in August 2025 closed its fifth Royalty and Credit Opportunities Fund with $1.86 billion in commitments, aimed at providing non-dilutive capital to growth-stage healthcare companies.

• Official Website: orbimed.com ↗
• Headquarters: New York, NY (London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya)
• Assets Under Management: Over $17 billion, by the firm’s own account
• Strategies: Private equity, public equity, royalty and credit
• Why They Stand Out: OrbiMed typically leads rounds and can invest across multiple funds in a single company, giving it unusual range for a founder who expects to raise repeatedly.

---

ARCH Venture Partners ↗

Best For: Academic founders with a platform rather than a product

ARCH Venture Partners is a Chicago-based firm that specializes in co-founding companies out of university laboratories, national research institutions and corporate research groups. Rather than waiting for a company to exist, ARCH frequently helps incorporate it. Its portfolio has included Illumina, Juno Therapeutics, Alnylam and Sana Biotechnology.

• Official Website: archventure.com ↗
• Headquarters: Chicago, IL
• Stage: Company creation and first institutional cheque
• Portfolio Has Included: Illumina, Juno Therapeutics, Alnylam, Sana Biotechnology
• Why They Stand Out: For founders coming directly out of academic research, ARCH is one of the small number of firms structurally set up to write the first cheque.

---

Flagship Pioneering ↗

Best For: Co-investment at later stages, rather than a cold pitch

Flagship Pioneering, based in Cambridge, Massachusetts, does not primarily invest in companies founded by other people — it invents them. The firm runs a systematic process that generates scientific hypotheses internally, funds them as explorations, and spins the survivors out as operating companies. Moderna is the best-known result.

• Official Website: flagshippioneering.com ↗
• Headquarters: Cambridge, MA
• Model: Internal company creation from self-generated scientific hypotheses
• Best-Known Result: Moderna
• Why They Stand Out: Flagship’s model means it is rarely the right target for a cold pitch, but it is one of the most consequential capital allocators in biotechnology and a frequent co-investor at later stages.

---

Third Rock Ventures ↗

Best For: Founders who want deep operational involvement, not a passive board seat

Third Rock Ventures is a Boston firm built around company creation in therapeutics. Its partners routinely take interim operating roles inside the companies they launch, and the firm is known for backing ambitious, science-heavy platforms and staffing them from its own network.

• Official Website: thirdrockventures.com ↗
• Headquarters: Boston, MA
• Focus: Therapeutics company creation
• Why They Stand Out: Founders working with Third Rock should expect deep involvement rather than a passive board seat.

---

Versant Ventures ↗

Best For: Discovery-stage biotech aimed at a pharma acquisition

Versant Ventures invests exclusively in biotechnology and runs discovery engines in North America and Europe, including operations in Basel and Vancouver, that build companies in-house before external financing. The firm has a long record of taking assets from discovery through to acquisition by large pharmaceutical companies.

• Official Website: versantventures.com ↗
• Focus: Biotechnology, exclusively
• Discovery Engines: North America and Europe, including Basel and Vancouver
• Why They Stand Out: Its structure is designed around taking assets from discovery through to pharma acquisition.

---

Atlas Venture ↗

Best For: First-time biotech founders who want to understand how a firm actually thinks

Atlas Venture is a Cambridge, Massachusetts firm that concentrates on seed-stage biotech and builds a substantial share of its portfolio itself. The firm is unusually transparent about its model, publishing detailed writing on how it forms companies and how it thinks about early biotech risk.

• Official Website: atlasventure.com ↗
• Headquarters: Cambridge, MA
• Stage: Seed-led biotech
• Why They Stand Out: For a first-time founder, Atlas’s public writing on company formation and early biotech risk is one of the most useful things any firm on this list makes available.

---

Deerfield Management ↗

Best For: Companies that want one investor from the bench through to the public markets

Deerfield Management is a New York healthcare investment firm that spans private venture, public equity, structured financing and research partnerships with academic institutions. It operates the Cure campus in Manhattan as a hub for healthcare innovation.

• Official Website: deerfield.com ↗
• Headquarters: New York, NY
• Strategies: Private venture, public equity, structured finance, academic research partnerships
• Notable: Operates the Cure campus in Manhattan
• Why They Stand Out: Deerfield’s range means it can fund a company at the bench and still be a holder years after an IPO.

---

RA Capital Management ↗

Best For: Crossover rounds immediately preceding a public offering

RA Capital Management is a Boston crossover firm investing in drug developers, diagnostics and medtech from private rounds through public markets. The firm is known for its in-house research effort, which maps entire therapeutic landscapes before committing, and for participating in the private rounds that immediately precede a public offering.

• Official Website: racap.com ↗
• Headquarters: Boston, MA
• Focus: Drug developers, diagnostics, medtech
• Verifiability: Files quarterly 13F reports with the SEC, making its public positions unusually easy to verify
• Why They Stand Out: An in-house research effort that maps entire therapeutic landscapes before the firm commits.

---

Perceptive Advisors ↗

Best For: Clinical and commercial-stage companies that want to avoid dilution

Perceptive Advisors is a New York firm investing exclusively in life sciences across public equity, venture and credit. Its credit arm provides debt to clinical and commercial-stage biotech companies that want to avoid dilution.

• Official Website: perceptivelife.com ↗
• Headquarters: New York, NY
• Strategies: Public equity, venture, credit
• Why They Stand Out: The credit arm makes Perceptive relevant at a stage when most venture firms are no longer the right fit.

---

Foresite Capital ↗

Best For: Companies at the intersection of biology and computation

Foresite Capital is a multi-stage healthcare firm investing across therapeutics, diagnostics, tools and health data, with a company-creation arm that builds businesses at the intersection of biology and computation. The firm invests from early venture through crossover rounds and public markets.

• Official Website: foresitecapital.com ↗
• Focus: Therapeutics, diagnostics, tools, health data
• Stage: Early venture through crossover and public markets
• Why They Stand Out: A dedicated company-creation arm alongside multi-stage investing.

---

The Column Group ↗

Best For: Platform companies with long development timelines

The Column Group is a San Francisco firm that takes deliberately concentrated positions in a small number of drug discovery platform companies. Its partners come predominantly from scientific and operating backgrounds rather than finance.

• Official Website: thecolumngroup.com ↗
• Headquarters: San Francisco, CA
• Approach: Deliberately concentrated positions in a small number of platform companies
• Why They Stand Out: Known for holding through long development timelines rather than optimizing for a quick markup.

---

New Enterprise Associates (NEA) ↗

Best For: Companies that want one investor from seed through growth

New Enterprise Associates is one of the largest venture firms in the world and has run a dedicated healthcare practice for decades alongside its technology business. Its healthcare team covers biopharma, medical devices and healthcare services.

• Official Website: nea.com ↗
• Focus: Biopharma, medical devices, healthcare services
• Stage: Seed through growth
• Why They Stand Out: Scale that allows NEA to lead seed rounds and still fund a company through growth stages.

---

Venrock ↗

Best For: Care delivery, health insurance technology and policy-literate capital

Venrock traces its origins to the Rockefeller family office and today invests across healthcare and technology. In healthcare it is particularly active in care delivery, health insurance technology and biotechnology.

• Official Website: venrock.com ↗
• Origins: The Rockefeller family office
• Focus: Care delivery, health insurance technology, biotechnology
• Why They Stand Out: Its partners publish extensively on healthcare policy and economics — a useful signal of how the firm actually thinks.

---

F-Prime Capital ↗

Best For: Founders who need flexibility on timeline

F-Prime Capital is a venture firm affiliated with the family behind Fidelity Investments, investing in healthcare and technology across the US, Europe and Asia. In healthcare it backs therapeutics, medical technology and health IT.

• Official Website: fprimecapital.com ↗
• Focus: Therapeutics, medical technology, health IT
• Geography: US, Europe, Asia
• Why They Stand Out: Because F-Prime invests permanent capital rather than raising from outside limited partners, it has more flexibility on timeline than a conventional fund.

---

SR One ↗

Best For: Biotech founders who want pharma relationships without a corporate parent

SR One was founded in 1985 as the venture arm of GlaxoSmithKline and completed its spinout in 2020, closing a $500 million first independent fund with GSK as its largest investor. A second fund of $600 million followed in 2023, backed by additional pharmaceutical companies as well as institutional investors. The firm invests in biotechnology from seed and Series A through to crossover rounds.

• Official Website: srone.com ↗
• Offices: San Francisco and London
• Funds: $500M first independent fund (2020); $600M second fund (2023)
• Portfolio Has Included: CRISPR Therapeutics, Nimbus Therapeutics, Arcellx
• Why They Stand Out: Its history gives it unusually deep pharma relationships without a current corporate parent’s strategic constraints.

---

Tier 1 Healthcare VCs and Global Life Sciences Funds

In practice, “Tier 1” describes the fifteen to twenty firms whose participation in a round changes how everyone else prices it. They consistently raise funds of $500 million or more, have led multiple companies to approval or to a significant exit, and are the names a later-stage investor looks for on a cap table before doing their own diligence.

In healthcare, tier is less about brand than about domain: a firm that is Tier 1 in oncology therapeutics may be irrelevant to a company selling software to health systems. The firms below carry that weight in their respective domains, across Europe, Asia and the US.

Novo Holdings ↗

Best For: Long-hold capital with no fund end-date

Novo Holdings is the Copenhagen-based holding and investment company of the Novo Nordisk Foundation, and it controls the Foundation’s stakes in Novo Nordisk and Novonesis. It is one of the largest life sciences investors in Europe, investing across seed venture, growth equity, principal investments and public equities.

• Official Website: novoholdings.dk ↗
• Headquarters: Copenhagen, Denmark
• Structure: Evergreen — not managing to a fund’s end date
• Why They Stand Out: Its evergreen structure shows in how long it is willing to hold.

---

Sofinnova Partners ↗

Best For: European biotech companies raising a first institutional round

Sofinnova Partners is a Paris-based venture firm and one of the longest-established life sciences investors in Europe, running dedicated strategies across biopharma, medtech, industrial biotechnology and digital medicine. It is frequently the first institutional investor in European biotech companies.

• Official Website: sofinnovapartners.com ↗
• Headquarters: Paris, France
• Strategies: Biopharma, medtech, industrial biotechnology, digital medicine
• Important Note: Sofinnova Partners and the US-based Sofinnova Investments are separate firms with separate teams.
• Why They Stand Out: A natural first call for a founder building outside the US.

---

Forbion ↗

Best For: European therapeutics aiming at a pharma acquisition

Forbion is a Netherlands-based life sciences venture firm investing across Europe and North America, with strategies covering early-stage company building and later-stage growth.

• Official Website: forbion.com ↗
• Headquarters: Netherlands
• Geography: Europe and North America
• Why They Stand Out: A strong record of taking European therapeutics companies through to acquisition by large pharma.

---

Syncona ↗

Best For: Founders who want to see an investor’s actual numbers before pitching

Syncona is unusual: it is a London-listed investment company that founds and funds life science businesses from its own permanent balance sheet, with roots in the Wellcome Trust.

• Official Website: synconaltd.com ↗
• Listing: London Stock Exchange
• Roots: The Wellcome Trust
• Why They Stand Out: Because it is publicly listed, Syncona publishes annual and interim reports describing its portfolio and valuations in detail — making it one of the most transparent investors on this list.

---

Abingworth ↗

Best For: Companies that may need capital from venture through buyout

Abingworth is a transatlantic life sciences investment firm with teams in London, Boston and the San Francisco Bay Area. Founded in 1973, it has deployed roughly $3 billion of equity behind more than 175 life sciences companies across 14 dedicated funds.

• Official Website: abingworth.com ↗
• Offices: London, Boston, San Francisco Bay Area
• Founded: 1973
• Track Record: Roughly $3 billion of equity across 14 funds and 175+ companies
• Portfolio Has Included: Alnylam, Galapagos
• Why They Stand Out: Carlyle acquired the firm in 2022, giving it access to capital across the full range from venture through buyout.

---

Frazier Healthcare Partners ↗

Best For: Founders who know which of two very different mandates they are pitching

Frazier Healthcare Partners, based in Seattle, runs two distinct businesses: a life sciences venture arm that creates and funds therapeutics companies, and a healthcare growth buyout arm that acquires healthcare services and products businesses.

• Official Website: frazierhealthcare.com ↗
• Headquarters: Seattle, WA
• Two Arms: Life sciences venture; healthcare growth buyout
• Why They Stand Out: Founders should be clear which team they are approaching, as the two have very different mandates.

---

Vivo Capital ↗

Best For: Companies planning development or commercialization in China

Vivo Capital is a Palo Alto firm investing across the healthcare industry in both the US and Asia, spanning venture capital, growth equity, buyout and public equity strategies.

• Official Website: vivocapital.com ↗
• Headquarters: Palo Alto, CA
• Strategies: Venture, growth equity, buyout, public equity
• Why They Stand Out: Its cross-border presence makes it a common partner for companies planning to run development or commercialization in China.

---

Lilly Asia Ventures ↗

Best For: Biomedical companies operating between Asia and the United States

Lilly Asia Ventures began in 2008 as a corporate venture subsidiary of Eli Lilly and spun out to become an independent investment management firm in 2011. Headquartered in Shanghai with offices in Hong Kong and Palo Alto, it invests globally across biopharmaceuticals, medical technologies and diagnostics, from seed stage through publicly traded companies.

• Official Website: lavfund.com ↗
• Headquarters: Shanghai (Hong Kong, Palo Alto)
• History: Founded inside Eli Lilly in 2008; independent since 2011
• Team: More than 50 investment and scientific professionals
• Why They Stand Out: One of the largest biomedical venture franchises operating between Asia and the United States.

---

Qiming Venture Partners ↗

Best For: Healthcare companies operating across China and the US

Qiming Venture Partners invests across China and the United States and runs a substantial dedicated healthcare practice covering biotechnology, medical devices, diagnostics and healthcare services alongside its technology business.

• Official Website: qimingvc.com ↗
• Geography: China and the United States
• Focus: Biotechnology, medical devices, diagnostics, healthcare services
• Why They Stand Out: One of the most established healthcare investors operating across both markets.

---

Casdin Capital ↗

Best For: Research tools, diagnostics and genomics companies

Casdin Capital is a New York firm focused on the life sciences innovation ecosystem, with particular depth in research tools, diagnostics and genomics. It invests in both private and public companies.

• Official Website: casdincapital.com ↗
• Headquarters: New York, NY
• Focus: Research tools, diagnostics, genomics
• Why They Stand Out: An active participant in the tools and platform companies underpinning modern drug discovery.

---

Digital Health and Health Tech Investors

Digital health capital behaves differently from therapeutics capital. These firms underwrite reimbursement, clinical impact and enterprise sales cycles rather than regulatory approval — and several of them offer buyer access as the substantive part of the deal.

General Catalyst ↗

Best For: Companies aligned with a health assurance thesis, at almost any stage

General Catalyst is a multi-stage firm whose health assurance thesis has made it one of the most active and most consequential investors in US healthcare. Beyond conventional investing, the firm has moved into operating health systems directly through its Health Assurance Transformation Company.

• Official Website: generalcatalyst.com ↗
• Stage: Multi-stage
• Notable: Operates health systems directly via its Health Assurance Transformation Company
• 2025 Activity: Rock Health identified General Catalyst as one of three investors — alongside Andreessen Horowitz and Kleiner Perkins — that each participated in at least five rounds of $100 million or more during 2025
• Why They Stand Out: Rock Health found that Series A rounds including these three firms averaged $24.1 million, against $18.9 million without.

---

Andreessen Horowitz (Bio + Health) ↗

Best For: TechBio and AI-driven drug discovery, from seed through growth

The Bio + Health practice at Andreessen Horowitz invests across TechBio, AI-driven drug discovery, care delivery and healthcare infrastructure, from seed through growth. The team runs a dedicated Bio + Health seed programme and publishes heavily on where computation meets biology.

• Official Website: a16z.com/bio-health ↗
• Focus: TechBio, AI-driven drug discovery, care delivery, healthcare infrastructure
• Stage: Seed through growth, with a dedicated Bio + Health seed programme
• Why They Stand Out: One of the three firms Rock Health named among 2025’s most active participants in healthcare megadeals.

---

GV ↗

Best For: Founders who want technical depth without pharma strategic conflicts

GV is Alphabet’s venture arm and one of the most consistently active investors in life sciences and health technology, with healthcare representing a substantial share of its overall portfolio. Its healthcare team invests from seed through growth across therapeutics, diagnostics, AI-enabled drug discovery and health infrastructure.

• Official Website: gv.com ↗
• Parent: Alphabet
• Stage: Seed through growth
• Why They Stand Out: GV brings Google’s technical depth without the strategic conflicts a pharmaceutical corporate arm carries.

---

Kleiner Perkins ↗

Best For: Therapeutics platforms and health software that need a lead investor

Kleiner Perkins invests across healthcare, life sciences and software from its Menlo Park base. The firm backs both therapeutics platforms and health software, and is typically a lead investor.

• Official Website: kleinerperkins.com ↗
• Headquarters: Menlo Park, CA
• Focus: Healthcare, life sciences, software
• Why They Stand Out: The third firm Rock Health singled out for participating in at least five healthcare megadeals in 2025.

---

Oak HC/FT ↗

Best For: Value-based care, healthcare payments and provider enablement at growth stage

Oak HC/FT invests exclusively in healthcare and fintech, concentrating on growth-stage companies in value-based care, healthcare payments, provider enablement and health infrastructure.

• Official Website: oakhcft.com ↗
• Focus: Healthcare and fintech, exclusively
• Stage: Growth
• Why They Stand Out: For a healthcare services or software company past the earliest stage, Oak HC/FT is one of the most specialized options available.

---

Define Ventures ↗

Best For: Early digital health companies that need health system and payer access

Define Ventures is an early-stage firm investing solely in digital health, founded and led by a team with operating backgrounds in healthcare. The firm runs founder and executive communities that give portfolio companies direct access to health system and payer buyers.

• Official Website: definevc.com ↗
• Focus: Digital health, exclusively
• Stage: Early
• Why They Stand Out: Buyer access is often the hardest thing for a digital health startup to secure, and Define’s communities are built around it.

---

Flare Capital Partners ↗

Best For: Healthcare technology companies that need early customers as well as capital

Flare Capital Partners is a Boston firm investing exclusively in healthcare technology, from early through growth stage. It maintains a formal network of health system and payer executives who serve as advisors and early customers to portfolio companies.

• Official Website: flarecapital.com ↗
• Headquarters: Boston, MA
• Focus: Healthcare technology, exclusively
• Why They Stand Out: A formal network of health system and payer executives acting as advisors and early customers.

---

7wireVentures ↗

Best For: Consumer-directed digital health at the earliest stages

7wireVentures is a Chicago firm investing in consumer-directed digital health, founded by operators with a long record of building and exiting healthcare companies. It concentrates on early-stage companies changing how consumers interact with the health system.

• Official Website: 7wireventures.com ↗
• Headquarters: Chicago, IL
• Focus: Consumer-directed digital health
• Why They Stand Out: Founded by operators with a long record of building and exiting healthcare companies.

---

Transformation Capital ↗

Best For: Digital health companies that have outgrown their early-stage syndicate

Transformation Capital invests at growth stage in healthcare technology, writing larger cheques into companies with established commercial traction.

• Official Website: transformcap.com ↗
• Focus: Healthcare technology
• Stage: Growth, with established commercial traction
• Why They Stand Out: A natural next investor for a digital health company that has outgrown its early-stage syndicate.

---

Frist Cressey Ventures ↗

Best For: Companies that need access to healthcare operators and policymakers

Frist Cressey Ventures is a Nashville firm co-founded by former US Senate Majority Leader and transplant surgeon Bill Frist, investing in healthcare services and technology.

• Official Website: fcventures.com ↗
• Headquarters: Nashville, TN
• Focus: Healthcare services and technology
• Why They Stand Out: Access to healthcare operators and policymakers is its distinguishing asset.

---

Town Hall Ventures ↗

Best For: Medicare, Medicaid and value-based care companies

Town Hall Ventures invests in companies serving underserved and vulnerable populations, with a focus on Medicare, Medicaid and value-based care. It was co-founded by former CMS administrator Andy Slavitt.

• Official Website: townhallventures.com ↗
• Focus: Medicare, Medicaid, value-based care, underserved populations
• Co-Founder: Andy Slavitt, former CMS administrator
• Why They Stand Out: Combines a policy-literate view of reimbursement with early-stage capital.

---

LRVHealth ↗

Best For: Early-stage companies whose main obstacle is a first health system contract

LRVHealth describes its model as investing inside healthcare: its limited partners are provider systems, payers and other healthcare organizations, which then serve as customers and validators for portfolio companies.

• Official Website: lrvhealth.com ↗
• Model: Limited partners are provider systems, payers and other healthcare organizations
• Stage: Early
• Why They Stand Out: For an early-stage company whose main obstacle is a first health system contract, that structure is the point.

---

AlleyCorp ↗

Best For: Experienced operators looking for a company to run, not capital for one they started

AlleyCorp is a New York venture studio founded by Kevin Ryan that founds healthcare companies internally as well as investing externally. Several of its healthcare businesses were conceived in-house before a founding CEO was recruited.

• Official Website: alleycorp.com ↗
• Headquarters: New York, NY
• Model: Venture studio — founds companies internally and invests externally
• Why They Stand Out: Relevant to experienced operators looking for a company to run rather than capital for one they have started.

---

Strategic and Corporate Venture Arms

Corporate venture arms trade a slower process for something no financial investor can offer: distribution, clinical validation, or a route into a payer or health system. Founders should understand that these investors have a strategic mandate alongside a financial one, and should ask directly how that mandate interacts with commercial partnership discussions.

Optum Ventures ↗

Best For: Software and tech-enabled care that benefits from payer proximity

Optum Ventures is the venture arm of UnitedHealth Group’s Optum division and one of the most active strategic investors in health technology. It invests in software, data analytics and technology-enabled care delivery.

• Official Website: optumventures.com ↗
• Parent: UnitedHealth Group (Optum)
• Focus: Software, data analytics, technology-enabled care delivery
• Why They Stand Out: Proximity to the largest payer ecosystem in the United States — which is also the main question a founder should interrogate before taking the money.

---

CVS Health Ventures ↗

Best For: Companies that can plug into a retail and pharmacy footprint

CVS Health Ventures is the corporate venture arm of CVS Health, investing in digital health and care delivery companies that fit alongside its pharmacy, benefits and clinical assets.

• Official Website: cvshealthventures.com ↗
• Parent: CVS Health
• Focus: Digital health and care delivery
• Why They Stand Out: Its portfolio skews toward companies that can plug into a retail and pharmacy footprint.

---

Johnson & Johnson Innovation – JJDC ↗

Best For: Companies across pharmaceuticals, medtech and health technology

JJDC is the strategic venture arm of Johnson & Johnson, investing across pharmaceuticals, medical technology and health technology. It has been one of the longest-operating corporate venture groups in healthcare.

• Official Website: jnjinnovation.com ↗
• Parent: Johnson & Johnson
• Focus: Pharmaceuticals, medical technology, health technology
• Why They Stand Out: Operates alongside J&J’s innovation centres and incubators.

---

Novartis Venture Fund ↗

Best For: Therapeutics and platform companies weighing pharma corporate capital

The Novartis Venture Fund invests in therapeutics and platform companies, operating with an explicitly financial mandate and independence from Novartis’s business development function.

• Official Website: nvfund.com ↗
• Parent: Novartis
• Mandate: Explicitly financial, independent of Novartis business development
• Why They Stand Out: That separation is deliberate, and it is worth understanding when weighing pharma corporate capital.

---

Pfizer Ventures ↗

Best For: Early and mid-stage biotech adjacent to Pfizer’s research priorities

Pfizer Ventures is the New York-based venture arm of Pfizer, investing in early and mid-stage biotechnology companies in areas adjacent to Pfizer’s own research priorities.

• Official Website: pfizer.com/about/partners/venture-investments ↗
• Parent: Pfizer
• Stage: Early and mid-stage biotechnology
• Why They Stand Out: Among the larger pharma corporate venture funds by assets; typically invests as a syndicate participant rather than a lead.

---

Leaps by Bayer ↗

Best For: Cell and gene therapy, regenerative medicine and reproductive health

Leaps by Bayer is Bayer’s impact investment unit, backing companies pursuing what it defines as breakthroughs in health and agriculture — cell and gene therapy, regenerative medicine, and reproductive health among them.

• Official Website: leaps.bayer.com ↗
• Parent: Bayer
• Focus: Cell and gene therapy, regenerative medicine, reproductive health, agriculture
• Why They Stand Out: It invests with longer horizons than a typical corporate venture arm.

---

UPMC Enterprises ↗

Best For: Companies selling into providers that need clinical validation

UPMC Enterprises is the innovation and commercialization arm of the UPMC health system, funding and building healthcare technology and life sciences companies — frequently with UPMC itself as the first deployment site.

• Official Website: enterprises.upmc.com ↗
• Parent: UPMC health system
• Focus: Healthcare technology and life sciences
• Why They Stand Out: For a company selling into providers, that clinical validation can matter more than the cheque.

---

Illumina Ventures ↗

Best For: Companies applying sequencing and genomic technologies

Illumina Ventures is a genomics-focused venture firm associated with Illumina, investing in companies applying sequencing and genomic technologies across diagnostics, therapeutics and research tools.

• Official Website: illuminaventures.com ↗
• Associated With: Illumina
• Focus: Diagnostics, therapeutics and research tools built on genomics
• Why They Stand Out: A dedicated genomics lens rather than a general healthcare mandate.

---

Family Offices Investing in Healthcare

Family offices are the least transparent capital source in healthcare. Most single family offices are exempt from registering with the SEC under the family office rule, which means they publish nothing — no portfolio, no assets under management, no deal history. The firms below are included because their healthcare activity is documented in their own public statements or in the announcements of the companies they backed. We have not estimated deal counts for any of them, and we would treat any list that claims to rank family offices by deal volume with real scepticism.

Family offices are worth pursuing precisely because their capital has no fund life attached. They can hold a therapeutics company through a decade of development without a partnership meeting about the fund’s vintage. They are also, as a rule, reached only through introduction.

Emerson Collective ↗

Best For: Cancer research and health equity

Emerson Collective, founded by Laurene Powell Jobs, operates as a for-profit organization combining philanthropy and investment. In healthcare its work has centred on cancer research and on health equity, including significant commitments to cancer immunotherapy research.

• Official Website: emersoncollective.com ↗
• Founder: Laurene Powell Jobs
• Structure: For-profit organization combining philanthropy and investment
• Healthcare Focus: Cancer research, health equity, cancer immunotherapy

---

Bezos Expeditions ↗

Best For: Longevity research and biotechnology at scale

Bezos Expeditions manages Jeff Bezos’s personal investments across early and late-stage ventures. In healthcare and life sciences it has backed longevity research and biotechnology companies.

• Official Website: bezosexpeditions.com ↗
• Principal: Jeff Bezos
• Stage: Early and late-stage
• Why They Stand Out: Generally invests at scale and with long time horizons.

---

Dolby Family Ventures ↗

Best For: Early-stage therapeutics for neurodegenerative disease

Dolby Family Ventures is the venture arm of the Dolby family office, with an explicit focus on neurodegenerative disease and particularly Alzheimer’s. It invests at early stages in therapeutics addressing conditions that affected the family directly.

• Official Website: dolbyventures.com ↗
• Focus: Neurodegenerative disease, particularly Alzheimer’s
• Stage: Early
• Why They Stand Out: A clear illustration of a common and underappreciated driver of family office healthcare investing.

---

B-FLEXION (formerly Waypoint Capital) ↗

Best For: Life sciences companies looking for operating heritage alongside capital

B-FLEXION is the investment office of the Bertarelli family, whose wealth originated in the biopharmaceutical company Serono. It invests across life sciences and healthcare alongside other asset classes. The firm previously operated under the Waypoint Capital name.

• Official Website: bflexion.com ↗
• Family: Bertarelli
• Origins: Serono, the biopharmaceutical company
• Name Change: Previously known as Waypoint Capital
• Why They Stand Out: Genuine operating heritage in the sector, not just allocation to it.

---

Iconiq Capital ↗

Best For: Healthcare technology alongside enterprise software

Iconiq Capital is a multi-family office and investment firm serving technology founders and executives, and its growth investing arm has been active in healthcare technology alongside enterprise software.

• Official Website: iconiq.com ↗
• Structure: Multi-family office and investment firm
• Focus: Healthcare technology and enterprise software at growth stage
• Why They Stand Out: It sits at the boundary between family office and institutional investor.

---

Athos Service

Athos is the family office of Thomas and Andreas Strüngmann, the twin brothers who built and sold the generics company Hexal. Athos was the founding investor behind BioNTech and remains one of the most significant private backers of European biotechnology. It is among the clearest examples of what family office capital can do in life sciences: patient, concentrated and willing to fund science through years without revenue. Consistent with the pattern described above, Athos maintains no public investor website — which is exactly why it is reached only through introduction.

---

Pritzker Vlock Family Office

The Pritzker Vlock Family Office, based in New Haven, invests in early-stage companies with a meaningful concentration in healthcare and life sciences, frequently as a first institutional cheque in companies emerging from the Northeast research ecosystem. Like most single family offices, it publishes no public portfolio or investor site.

---

Full Directory: 109 Healthcare Investment Firms

The profiles above cover the firms we are asked about most often. The table below is the complete list, including firms we have not written up individually. Categories are ours; the short descriptions are drawn from each firm’s own published positioning.

Firm	Category	Focus
OrbiMed	Healthcare VC & Growth	New York firm investing across healthcare venture, growth, public equity and royalty/credit strategies.
ARCH Venture Partners	Healthcare VC & Growth	Chicago firm that co-founds and seeds companies out of university and national laboratory research.
Flagship Pioneering	Healthcare VC & Growth	Cambridge, MA firm that conceives and builds its own biotech companies in-house; founded Moderna.
Third Rock Ventures	Healthcare VC & Growth	Boston firm that launches and incubates therapeutics companies with hands-on company creation.
Versant Ventures	Healthcare VC & Growth	Biotech firm running company-creation studios across the US, Canada and Europe.
5AM Ventures	Healthcare VC & Growth	Early-stage life sciences firm building therapeutics and platform companies from seed.
Atlas Venture	Healthcare VC & Growth	Cambridge, MA seed-led biotech firm that builds companies through its own venture creation engine.
Polaris Partners	Healthcare VC & Growth	Boston firm investing across healthcare and life sciences from seed through growth.
Frazier Healthcare Partners	Healthcare VC & Growth	Seattle firm running both a life sciences venture arm and a healthcare growth buyout arm.
Deerfield Management	Healthcare VC & Growth	New York healthcare investment firm spanning private, public and structured capital.
RA Capital Management	Healthcare VC & Growth	Boston crossover firm investing in drug developers and medtech from private rounds into public markets.
Perceptive Advisors	Healthcare VC & Growth	New York life sciences firm combining public equity, venture and credit strategies.
venBio	Healthcare VC & Growth	Therapeutics-focused firm investing in private and public biotechnology.
Foresite Capital	Healthcare VC & Growth	Multi-stage healthcare firm and company builder across therapeutics, diagnostics and health data.
Casdin Capital	Healthcare VC & Growth	New York firm focused on life sciences innovation, tools and diagnostics.
Cormorant Asset Management	Healthcare VC & Growth	Boston firm investing across private and public biotechnology.
EcoR1 Capital	Healthcare VC & Growth	San Francisco biotech investment firm active in private rounds and public markets.
Vida Ventures	Healthcare VC & Growth	Therapeutics-focused venture firm backing clinical-stage biotech.
The Column Group	Healthcare VC & Growth	San Francisco firm taking concentrated, founder-led positions in drug discovery platforms.
Westlake Village BioPartners	Healthcare VC & Growth	Los Angeles-area firm building biotech companies in Southern California.
Longitude Capital	Healthcare VC & Growth	Venture firm investing across biotechnology and medical technology.
New Enterprise Associates (NEA)	Healthcare VC & Growth	Generalist firm with a long-standing dedicated healthcare practice alongside technology.
Canaan Partners	Healthcare VC & Growth	Early-stage firm investing across biotechnology and technology.
Venrock	Healthcare VC & Growth	Firm with roots in the Rockefeller family office, investing in healthcare and technology.
F-Prime Capital	Healthcare VC & Growth	Venture firm affiliated with the Fidelity founding family, investing in healthcare and technology.
SR One	Healthcare VC & Growth	Transatlantic biotech firm founded in 1985 as GSK’s venture arm and independent since 2020.
Novo Holdings	Healthcare VC & Growth	Copenhagen-based holding and investment company of the Novo Nordisk Foundation.
Forbion	Healthcare VC & Growth	Netherlands-based European life sciences venture firm.
EQT Life Sciences	Healthcare VC & Growth	European life sciences arm of EQT, formed from Life Sciences Partners (LSP).
Gilde Healthcare	Healthcare VC & Growth	Dutch firm investing in healthtech and European healthcare services.
Medicxi	Healthcare VC & Growth	London and Geneva firm focused on asset-centric drug development.
Abingworth	Healthcare VC & Growth	Transatlantic life sciences firm, part of Carlyle since 2022, with teams in London, Boston and the Bay Area.
SV Health Investors	Healthcare VC & Growth	Transatlantic firm investing in biotech, medtech and dementia-focused strategies.
Syncona	Healthcare VC & Growth	London-listed company that founds and funds life science businesses.
Sofinnova Partners	Healthcare VC & Growth	Paris-based European life sciences venture firm.
Sofinnova Investments	Healthcare VC & Growth	US biotech venture firm, operating separately from the Paris firm of a similar name.
Andera Partners	Healthcare VC & Growth	Paris firm investing in life sciences and mid-cap growth.
Jeito Capital	Healthcare VC & Growth	Paris growth-stage biopharma investor.
Kurma Partners	Healthcare VC & Growth	European early-stage life sciences firm.
Pontifax	Healthcare VC & Growth	Israel-based life sciences group running venture and credit funds.
aMoon	Healthcare VC & Growth	Israel-based healthtech and life sciences fund.
Lightstone Ventures	Healthcare VC & Growth	Venture firm investing in biotechnology and medical devices.
Lilly Asia Ventures	Healthcare VC & Growth	Shanghai-headquartered biomedical firm, founded inside Eli Lilly in 2008 and independent since 2011.
Qiming Venture Partners	Healthcare VC & Growth	China and US firm with a substantial dedicated healthcare practice.
Vivo Capital	Healthcare VC & Growth	Palo Alto firm investing across healthcare in the US and Asia.
CBC Group	Healthcare VC & Growth	Asia-focused healthcare investment firm.
General Catalyst	Digital Health & Health Tech	Multi-stage firm with a large health assurance practice and its own health system arm.
Andreessen Horowitz (Bio + Health)	Digital Health & Health Tech	a16z’s dedicated bio and healthcare practice, spanning TechBio and care delivery.
Kleiner Perkins	Digital Health & Health Tech	Menlo Park firm investing across healthcare, life sciences and software.
GV	Digital Health & Health Tech	Alphabet’s venture arm; life sciences and health tech are a large share of its portfolio.
Khosla Ventures	Digital Health & Health Tech	Menlo Park firm backing early-stage healthcare and AI-driven medicine.
Oak HC/FT	Digital Health & Health Tech	Growth-stage firm dedicated to healthcare and fintech.
Bessemer Venture Partners	Digital Health & Health Tech	Multi-stage firm with a dedicated healthcare investing team.
Define Ventures	Digital Health & Health Tech	Early-stage firm investing exclusively in digital health.
7wireVentures	Digital Health & Health Tech	Chicago firm investing in consumer-directed digital health.
Flare Capital Partners	Digital Health & Health Tech	Boston healthcare technology venture firm.
Transformation Capital	Digital Health & Health Tech	Growth-stage healthcare technology investment firm.
Frist Cressey Ventures	Digital Health & Health Tech	Nashville firm co-founded by Bill Frist investing in healthcare services and technology.
LRVHealth	Digital Health & Health Tech	“Inside healthcare” firm investing alongside provider and payer limited partners.
Echo Health Ventures	Digital Health & Health Tech	Firm backed by Cambia and Mosaic Health investing in healthcare growth companies.
.406 Ventures	Digital Health & Health Tech	Boston firm investing in digital health and enterprise technology.
Bain Capital Ventures	Digital Health & Health Tech	Early and growth-stage firm active in healthcare software and services.
Insight Partners	Digital Health & Health Tech	New York software growth firm active in health IT and TechBio.
Thrive Capital	Digital Health & Health Tech	New York firm investing across internet, software and healthcare.
Founders Fund	Digital Health & Health Tech	San Francisco firm investing in biotechnology and health infrastructure.
Lux Capital	Digital Health & Health Tech	New York firm backing science and technology companies, including health and bio.
B Capital	Digital Health & Health Tech	Global growth firm with a dedicated healthcare practice.
SignalFire	Digital Health & Health Tech	Data-driven early-stage firm with a healthcare vertical.
Town Hall Ventures	Digital Health & Health Tech	New York firm focused on underserved populations and value-based care.
AlleyCorp	Digital Health & Health Tech	New York venture studio that founds healthcare companies in-house.
Rock Health Capital	Digital Health & Health Tech	Seed-stage digital health fund affiliated with the Rock Health research group.
Optum Ventures	Strategic & Corporate	Venture arm of UnitedHealth Group’s Optum division.
CVS Health Ventures	Strategic & Corporate	Corporate venture arm of CVS Health.
Blue Venture Fund	Strategic & Corporate	Collaborative fund investing on behalf of Blue Cross Blue Shield companies.
UPMC Enterprises	Strategic & Corporate	Innovation and investment arm of the UPMC health system.
Mayo Clinic Ventures	Strategic & Corporate	Commercialization and venture arm of Mayo Clinic.
Cleveland Clinic Ventures	Strategic & Corporate	Commercialization and venture arm of Cleveland Clinic.
Providence Ventures	Strategic & Corporate	Venture arm of the Providence health system.
Ascension Ventures	Strategic & Corporate	Strategic venture firm affiliated with Ascension.
Kaiser Permanente Ventures	Strategic & Corporate	Venture arm of Kaiser Permanente.
Johnson & Johnson Innovation – JJDC	Strategic & Corporate	Strategic venture arm of Johnson & Johnson.
Novartis Venture Fund	Strategic & Corporate	Corporate venture fund of Novartis.
Pfizer Ventures	Strategic & Corporate	New York-based corporate venture arm of Pfizer.
AbbVie Ventures	Strategic & Corporate	Corporate venture arm of AbbVie.
Amgen Ventures	Strategic & Corporate	Corporate venture fund of Amgen, formed in 2004 to back early-stage therapeutics companies.
Roche Venture Fund	Strategic & Corporate	Corporate venture fund of Roche.
Bristol Myers Squibb	Strategic & Corporate	Corporate venture and business development activity of BMS.
Merck Global Health Innovation Fund	Strategic & Corporate	Merck’s healthcare technology venture fund.
Sanofi Ventures	Strategic & Corporate	Corporate venture arm of Sanofi.
Takeda Ventures	Strategic & Corporate	Corporate venture arm of Takeda.
Boehringer Ingelheim Venture Fund	Strategic & Corporate	Corporate venture fund of Boehringer Ingelheim.
Leaps by Bayer	Strategic & Corporate	Bayer’s impact investment unit targeting breakthroughs in health and agriculture.
Illumina Ventures	Strategic & Corporate	Genomics-focused venture firm associated with Illumina.
Philips Ventures	Strategic & Corporate	Corporate venture arm of Royal Philips.
Bezos Expeditions	Family Office	Jeff Bezos’s personal investment vehicle; has backed longevity and biotechnology ventures.
Cascade Investment / Gates Frontier	Family Office	Bill Gates’s private investment entities.
Emerson Collective	Family Office	Laurene Powell Jobs’s organization, active in health equity and cancer research.
Hillspire	Family Office	Family office of Eric and Wendy Schmidt.
Iconiq Capital	Family Office	Multi-family office and investment firm serving technology founders and executives.
Athos Service	Family Office	Family office of the Strüngmann brothers; founding backer of BioNTech.
Blue Pool Capital	Family Office	Family office associated with Joe Tsai.
B-FLEXION (formerly Waypoint Capital)	Family Office	Investment office of the Bertarelli family, with life sciences roots in Serono.
Dolby Family Ventures	Family Office	Family office of the Dolby family, focused on neurodegenerative disease.
Pritzker Vlock Family Office	Family Office	New Haven-based family office active in early-stage healthcare.
MSD Capital	Family Office	Michael Dell’s private investment firm.
Willett Advisors	Family Office	Manages the personal and philanthropic assets of Michael Bloomberg.
Cercano Management	Family Office	Investment firm with roots in the Paul Allen organization; life sciences among its focus areas.
Duquesne Family Office	Family Office	Stanley Druckenmiller’s family office.
Soros Fund Management	Family Office	Family office of George Soros.

Frequently Asked Questions About Top Healthcare Investors

Whether you are raising a seed round for a digital health company, taking a therapeutics platform to a Series A, looking to invest as an LP, or seeking a partnership with one of these firms, here are the answers founders ask us for most often.

How do you get in front of top healthcare VC firms?

Warm introduction remains by far the most effective route, and in healthcare the strongest introductions come from three sources: a physician or scientific advisor the firm already respects, a founder in their existing portfolio, or a banker or lawyer who has closed deals with them. Most firms publish a contact form or a submissions address, and some partners keep open inboxes, but cold inbound converts poorly in this sector. Sequence your outreach: identify the specific partner who covers your therapeutic area or care setting, read what they have published, and reference it.

How do you pitch a healthcare investor?

Healthcare investors underwrite different risk than technology investors, and the pitch has to reflect that. For therapeutics, they want the biology, the mechanism, the competitive landscape at the target level, and a credible regulatory path with named comparators. For digital health, they want evidence of clinical impact, a clear reimbursement or payment model, and proof that a real buyer has signed something. In both cases, the team’s domain credibility carries more weight than in almost any other sector — an investor is underwriting a decade of development, and they are assessing whether this team can survive it.

Do family offices invest in healthcare?

Yes, and increasingly directly rather than through funds. Family offices are significant sources of capital in biotechnology in particular, where their lack of a fund end-date suits long development timelines. The difficulty is access and information: most single family offices publish nothing, are not required to register with the SEC, and take meetings only through their existing networks. Founders generally reach them through advisors, syndicate partners, or personal connection to the family’s philanthropic or medical interests.

What is the difference between a healthcare VC and a healthcare private equity firm?

Venture firms buy minority stakes in companies that are not yet profitable, expecting most investments to fail and a small number to return the fund. Healthcare private equity firms buy control of established, cash-generating businesses — physician practices, outpatient facilities, healthcare services and products companies — and create value through operations, consolidation and leverage. Some firms on this list run both strategies under one roof, with entirely separate teams and mandates. Approach the right one.

Which healthcare investors are most active right now?

Activity concentrated significantly in 2025 and into 2026. Rock Health’s year-end analysis named Andreessen Horowitz, General Catalyst and Kleiner Perkins as the firms participating in the largest number of $100 million-plus digital health rounds, with at least five each. In therapeutics, the crossover funds — OrbiMed, RA Capital, Perceptive, Foresite, Casdin and Cormorant among them — have been the most visible participants in the rounds that precede public listings. “Most active” changes quarterly, and any list claiming a precise ranking of investor deal counts is drawing on paid database data rather than anything the firms publish themselves.